Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation
Jørgen Ankill,Zhi Zhao,Xavier Tekpli,Elin H. Kure,Vessela N. Kristensen,Anthony Mathelier,Thomas Fleischer
DOI: https://doi.org/10.1371/journal.pcbi.1012565
2024-11-24
PLoS Computational Biology
Abstract:Aberrant DNA methylation contributes to gene expression deregulation in cancer. However, these alterations' precise regulatory role and clinical implications are still not fully understood. In this study, we performed expression-methylation Quantitative Trait Loci (emQTL) analysis to identify deregulated cancer-driving transcriptional networks linked to CpG demethylation pan-cancer. By analyzing 33 cancer types from The Cancer Genome Atlas, we identified and confirmed significant correlations between CpG methylation and gene expression (emQTL) in cis and trans , both across and within cancer types. Bipartite network analysis of the emQTL revealed groups of CpGs and genes related to important biological processes involved in carcinogenesis including proliferation, metabolism and hormone-signaling. These bipartite communities were characterized by loss of enhancer methylation in specific transcription factor binding regions (TFBRs) and the CpGs were topologically linked to upregulated genes through chromatin loops. Penalized Cox regression analysis showed a significant prognostic impact of the pan-cancer emQTL in many cancer types. Taken together, our integrative pan-cancer analysis reveals a common architecture where hallmark cancer-driving functions are affected by the loss of enhancer methylation and may be epigenetically regulated. In this study, we assessed how changes in DNA methylation–an epigenetic modification—contribute to gene expression alterations across cancer types. Analyzing data from 33 different cancer types, we found that loss of methylation at specific DNA regions, known as CpG sites, is associated with the disruption of key biological processes driving cancer progression, such a cell division, hormone signaling and metabolism. The alterations in DNA methylation were most prominently occurring in enhancer regions, which are gene regulatory regions that can alter gene expression from a distance. Our analysis revealed that these methylation alterations are linked to patient outcomes, suggesting their potential as valuable prognostic markers. Moreover, we identified a recurring pattern of gene dysregulation across different cancer types, demonstrating a common underlying mechanism where the loss of enhancer methylation plays a pivotal role in cancer progression. This study enhances our understanding of how alterations in DNA methylation influence cancer behavior and highlights the possibilities for therapeutic strategies targeting these alterations.
biochemical research methods,mathematical & computational biology